SEC Comment Letter 0000000000-24-011137 to Camp4 Therapeutics Corp (CAMP) (CIK 0001736730) (CAMP)
Camp4 Therapeutics Corp (CAMP) (CIK 0001736730)
Date: Oct. 2, 2024 · CIK: 0001736730 · Accession: 0000000000-24-011137
AI Filing Summary & Sentiment
File numbers found in text: 333-282241
Letter
October 2, 2024 Josh Mandel-Brehm Chief Executive Officer CAMP4 Therapeutics Corp One Kendall Square Building 1400 West, 3rd Floor Cambridge, MA 02139 Re:CAMP4 Therapeutics Corp Amendment No. 1 to Registration Statement on Form S-1 Filed September 26, 2024 File No. 333-282241 Dear Josh Mandel-Brehm: We have reviewed your amended registration statement and have the following comments. Please respond to this letter by amending your registration statement and providing the requested information. If you do not believe a comment applies to your facts and circumstances or do not believe an amendment is appropriate, please tell us why in your response. After reviewing any amendment to your registration statement and the information you provide in response to this letter, we may have additional comments. Registration Statement on Form S-1 Prospectus Summary CMP-CPS-001: Potential treatment for urea cycle disorders, page 5 1.We note your disclosure on pages 5 and 130 that as of September 2024, the Safety Review Committee of your Phase 1 clinical trial of CMP-CPS-001 has reviewed all reported interim safety data, including treatment emergent adverse events from SAD cohorts 1 through 3, and that to date, "no safety trends of concern have been observed, and CMP-CPS-001 has been well tolerated." Please tell us whether any treatment related serious adverse events ("SAEs") occurred in your clinical trial, and if so, describe each SAE and quantify the number of occurrences. Alternatively, if true, affirmatively state that no SAEs occurred.
October 2, 2024 Page 2 Please contact Gary Newberry at 202-551-3761 or Mary Mast at 202-551-3613 if you have questions regarding comments on the financial statements and related matters. Please contact Lauren Hamill at 303-844-1008 or Joe McCann at 202-551-6262 with any other questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc:Thomas Danielski
Show Raw Text
October 2, 2024
Josh Mandel-Brehm
Chief Executive Officer
CAMP4 Therapeutics Corp
One Kendall Square
Building 1400 West, 3rd Floor
Cambridge, MA 02139
Re:CAMP4 Therapeutics Corp
Amendment No. 1 to Registration Statement on Form S-1
Filed September 26, 2024
File No. 333-282241
Dear Josh Mandel-Brehm:
We have reviewed your amended registration statement and have the following
comments.
Please respond to this letter by amending your registration statement and providing the
requested information. If you do not believe a comment applies to your facts and circumstances
or do not believe an amendment is appropriate, please tell us why in your response.
After reviewing any amendment to your registration statement and the information you
provide in response to this letter, we may have additional comments.
Registration Statement on Form S-1
Prospectus Summary
CMP-CPS-001: Potential treatment for urea cycle disorders, page 5
1.We note your disclosure on pages 5 and 130 that as of September 2024, the Safety
Review Committee of your Phase 1 clinical trial of CMP-CPS-001 has reviewed all
reported interim safety data, including treatment emergent adverse events from SAD
cohorts 1 through 3, and that to date, "no safety trends of concern have been observed,
and CMP-CPS-001 has been well tolerated." Please tell us whether any treatment related
serious adverse events ("SAEs") occurred in your clinical trial, and if so, describe each
SAE and quantify the number of occurrences. Alternatively, if true, affirmatively state
that no SAEs occurred.
October 2, 2024
Page 2
Please contact Gary Newberry at 202-551-3761 or Mary Mast at 202-551-3613 if you
have questions regarding comments on the financial statements and related matters. Please
contact Lauren Hamill at 303-844-1008 or Joe McCann at 202-551-6262 with any other
questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc:Thomas Danielski